SCHEMBL652836

SCHEMBL652836

O=c1[nH]cnc2sccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 7/20 0.52
PDPK1 O15530 2/20 0.52
ALDH1A1 P00352 3/20 0.46
RAB9A P51151 2/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CA12 O43570 1/20 0.46
ALOX15 P16050 1/20 0.46
CA9 Q16790 1/20 0.46
TNKS2 Q9H2K2 1/20 0.46
CYP1A2 P05177 1/20 0.45
TMIGD3 P0DMS9 1/20 0.45
CYP2C9 P11712 1/20 0.45
ADORA1 P30542 1/20 0.45
KMT2A Q03164 1/20 0.45
CHEK1 O14757 4/20 0.44
USP2 O75604 1/20 0.44
PKM P14618 1/20 0.44
KRAS P01116 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL913578 0.76 RAB9A (0.47) PARP1PDPK1ALDH1A1RAB9ALMNA
SCHEMBL27496307 0.76 CHEK1 (0.41) PARP1PDPK1ALDH1A1RAB9ALMNA
SCHEMBL269563 0.70
SCHEMBL120158 0.70
SCHEMBL17897153 0.68 PDPK1 (0.40) PARP1PDPK1ALDH1A1RAB9ALMNA
SCHEMBL2284623 0.68 PARP1 (0.43) PARP1PDPK1ALDH1A1SMN1; SMN2CA12
SCHEMBL3863547 0.68 CYP1A2 (0.45) PARP1PDPK1ALDH1A1RAB9ALMNA
SCHEMBL914620 0.67 CHEK1 (0.44) ALDH1A1RAB9ALMNASMN1; SMN2KMT2A
SCHEMBL16815323 0.67 CYP1A2 (0.60) PARP1PDPK1ALDH1A1RAB9ALMNA
SCHEMBL383127 0.67 KMT2A (0.44) PARP1PDPK1ALDH1A1LMNATNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4008716-A1 NOVEL INHIBITORS OF INSULIN-LIKE GROWTH FACTOR 2 MRNA BINDING PROTEINS Martin-Luther-Universität Halle-Wittenberg (DE) 2022-06-08 EP claimed
EP-4008717-A2 NOVEL INHIBITORS OF INSULIN-LIKE GROWTH FACTOR 2 MRNA BINDING PROTEINS Martin-Luther-Universität Halle-Wittenberg (DE) 2022-06-08 EP claimed
WO-2017100593-A1 THIENOPYRIMIDINONE NMDA RECEPTOR MODULATORS AND USES THEREOF LUC THERAPEUTICS (US) 2017-06-15 WO claimed
US-9445599-B2 Lignin-based microparticles for the controlled release of agricultural actives MONSANTO TECHNOLOGY LLC (US) 2016-09-20 US claimed
CN-105017277-A 2-substituted tetrahydrobenzo thieno pyrimidyl ketone derivative and preparation method and application thereof UNIV WENZHOU MEDICAL 2015-11-04 CN claimed
EP-2854534-A1 COMPOSITIIONS COMPRISING A BIOLOGICAL CONTROL AGENT AND AN INSECTICIDE Bayer Cropscience AG (DE) 2015-04-08 EP claimed
WO-2013178661-A1 COMPOSITIIONS COMPRISING A BIOLOGICAL CONTROL AGENT AND AN INSECTICIDE BAYER CROPSCIENCE AG (DE) 2013-12-05 WO claimed
US-8324227-B2 Thieno[2,3-D]-pyrimidin-4(3H)-one compounds with antifungal properties and process thereof FDC LIMITED (US) 2012-12-04 US claimed
CN-1922171-B Pyrimidine derivative ASKA PHARM CO LTD 2012-10-17 CN claimed
EP-2257555-B1 THIENO[2,3-D]-PYRIMIDINE-4(3H)-ONE COMPOUNDS WITH ANTIFUNGAL PROPERTIES AND PROCESS THEREOF NAT CHEMICAL LAB (IN) 2012-07-04 EP claimed
WO-2003005816-A1 LIGNIN MICROPARTICLES FOR CONTROLLED RELEASE OF AGRICULTURAL ACTIVES MONSANTO TECHNOLOGY, LLC (US) 2003-01-23 WO claimed
US-20030013612-A1 Lignin-based microparticles for the controlled release of agricultural actives MONSANTO TECHNOLOGY, L.L.C. (US) 2003-01-16 US claimed
US-6432965-B1 SYNERGISTIC MIXTURE SYNGENTA CROP PROTECTION, INC. 2002-08-13 US claimed
US-20020035038-A1 Fungicidal combinations comprising thieno[2,3-d]pyrimidin-4-one WALTER HARALD (CH) 2002-03-21 US claimed
US-6323208-B1 COMPOUNDS TO TREAT NEURODEGENERATIVE, PSYCHOTROPIC DRUG AND ALCOHOL INDUCED CENTRAL AND INDUCED CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS. PFIZER INC 2001-11-27 US claimed
EP-1124422-A1 FUNGICIDAL COMBINATIONS COMPRISING THIENO[2,3-d]PYRIMIDIN-4-ONE Syngenta Participations AG (CH) 2001-08-22 EP claimed
EP-1035773-A1 FUNGICIDAL COMBINATIONS COMPRISING THIENO 2,3-d]PYRIMIDIN-4-ONE Novartis AG (CH) 2000-09-20 EP claimed
WO-2000027200-A1 FUNGICIDAL COMBINATIONS COMPRISING THIENO[2,3-d]PYRIMIDIN-4-ONE SYNGENTA PARTICIPATIONS AG (CH) 2000-05-18 WO claimed
WO-1999027790-A1 FUNGICIDAL COMBINATIONS COMPRISING THIENO[2,3-d]PYRIMIDIN-4-ONE NOVARTIS AG (CH) 1999-06-10 WO claimed
EP-0733633-A1 Heterocyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-09-25 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035038-A1 Fungicidal combinations comprising thieno[2,3-d]pyrimidin-4-one MANBA, TPMT, TH PARP1 3222/4885PDPK1 4001/4885ALDH1A1 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.